Division of Nephrology and Hypertension

October 12, 2018

Targeting diabetic kidney disease

Pathways activated by the epidermal growth factor receptor may be attractive targets to treat diabetic kidney disease, according to new findings from Vanderbilt investigators.

By Sanjay Mishra
August 16, 2018

YAP after acute kidney injury

Activation of the signaling protein YAP may be a target for treating acute kidney injury, which affects up to 20 percent of hospitalized patients.

By Sanjay Mishra
June 28, 2018

Ikizler to succeed Harris as Nephrology and Hypertension director

Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.

By Bill Snyder
3d rendering white blood cells with red blood cells
April 10, 2018

Vanderbilt scientists test potential new way to treat anemia

Treatment of anemia caused by chronic kidney disease or other diseases often requires repeated — and costly — injections or infusions of an artificial form of the hormone erythropoietin (EPO), which stimulates production of red blood cells.

By Bill Snyder
March 15, 2018

Research explores barriers to kidney disease screening

New research by Vanderbilt nephrologists highlights potential barriers that may prevent black Americans from being screened for kidney disease.

By VUMC News and Communications
October 13, 2017

New tools to combat kidney fibrosis

Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.

By Leigh MacMillan
September 28, 2017

Major grant to enhance kidney disease research

Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease.
By Doug Campbell
September 11, 2017

Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
By VUMC News and Communications
August 31, 2017

End-stage kidney disease study seeks to delay dialysis

Vanderbilt University Medical Center (VUMC) is studying the safety of a possible treatment for diabetic kidney disease that would delay or prevent the need for kidney replacement such as dialysis.
By Kathy Whitney
May 11, 2017

EETs contribute to insulin sensitivity

Interventions that increase circulating levels of compounds called EETs may improve insulin sensitivity and treat hypertension.
By Leigh MacMillan
February 2, 2017

New Physician Science Doctoral Program graduates first student

As a fellow in pulmonary and critical care medicine at Vanderbilt University School of Medicine, Bradley Richmond, M.D., saw a lot of patients with chronic obstructive pulmonary disease (COPD), an inflammatory lung disease caused most often by long-term exposure to cigarette smoke.
By Bill Snyder
January 19, 2017

Surprising finding by VU team sheds light on fibrotic disease

Integrins are membrane proteins made up of combinations of different “alpha” and “beta” subunits that enable cells throughout the body to interact with their surroundings.
By Bill Snyder
November 21, 2016

Building the basement membrane

Vanderbilt researchers have discovered steps in the regulation of a key enzyme that builds the basement membrane, a structure that undergirds nearly all animal tissues.
By Bill Snyder
1 … 4 5 6 7 8 9